Plant ID: NPO21355
Plant Latin Name: Elsholtzia ciliata
Taxonomy Genus: Elsholtzia
Taxonomy Family: Lamiaceae
NCBI TaxonomyDB:
662901
Plant-of-the-World-Online:
90101-2
Antibacterial; Antipyretic; Antiviral; Astringent; Carminative; Depurative; Diaphoretic; Diuretic; Stomachic
Canada; Afghanistan; Nepal; Mongolia; Laos; Belarus; Turkey; Germany; China; Ukraine; Denmark; Poland; United States; Sweden; Vietnam; Thailand; Russia; Romania; Myanmar; South Africa; India; Japan; Taiwan
TSHR; NPSR1; | |
ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; | |
RECQL; ADK; HSD11B1; HSD17B1; HSD17B10; ALOX12; ALOX15; NOX4; POLB; | |
ACHE; | |
PIM1; MET; MAPK1; AXL; FLT3; CDK1; KDR; CDK8; IGF1R; AURKB; CSNK2A1; | |
CA12; CA7; CA4; | |
RORC; | |
ESR2; | |
NR1H4; | |
MMP9; MMP1; MMP12; MMP2; | |
HIF1A; NFKB1; | |
LMNA; FABP3; FABP4; MAPT; THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.664E-09 | 1.510E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.246E-09 | 5.985E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.350E-08 | 1.972E-05 | ALOX12, CDK1, CSNK2A1, FLT3, HIF1A, IGF1R, KDR, MAPK1, MMP12, MMP2, MMP9, PIM1, THPO, TSHR |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.737E-07 | 7.417E-05 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.301E-07 | 8.791E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.392E-07 | 1.154E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 5.012E-07 | 1.605E-04 | ADORA1, ADORA2A, CYP19A1, FFAR4, NFKB1, NR1H4 |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 5.670E-07 | 1.722E-04 | ADORA1, ADORA2A, ADORA3 |
MF | GO:0005488; binding | GO:0020037; heme binding | 9.419E-07 | 2.664E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.356E-06 | 3.474E-04 | ADORA1, ADORA2A, ADORA3 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.354E-06 | 3.474E-04 | CSNK2A1, HIF1A, KDR, MAPT |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.815E-06 | 6.009E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
MF | Unclassified; | GO:0004872; receptor activity | 5.458E-06 | 9.590E-04 | ADORA1, ADORA2A, ADORA3, AXL, ESR2, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, NR1H4, RORC, TSHR |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 6.567E-06 | 1.059E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 6.567E-06 | 1.059E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.265E-06 | 1.146E-03 | CA12, CA4, CA7 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 7.879E-06 | 1.225E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 8.925E-06 | 1.340E-03 | CDK1, CDK8, MAPK1 |
CC | GO:0044464; cell part | GO:0030673; axolemma | 8.925E-06 | 1.340E-03 | ADORA1, ADORA2A, MAPT |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.108E-05 | 1.609E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.455E-05 | 2.006E-03 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, HSD11B1, HSD17B1, HSD17B10, NOX4 |
BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 1.757E-05 | 2.348E-03 | ADORA2A, CYP19A1, FFAR1, HIF1A, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.967E-05 | 2.519E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.967E-05 | 2.519E-03 | ALOX12, ALOX15 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.967E-05 | 2.519E-03 | ADORA1, ADORA2A |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.394E-05 | 2.979E-03 | MMP1, MMP12, MMP2, MMP9 |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 2.505E-05 | 3.099E-03 | ALOX15, AURKB, HIF1A, KDR, MAPK1, MAPT, MET, MMP9, NOX4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.787E-05 | 3.409E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.144E-05 | 3.762E-03 | CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, RORC |
BP | GO:0009987; cellular process | GO:0030154; cell differentiation | 3.332E-05 | 3.901E-03 | AXL, CDK1, CYP1A1, FABP4, FFAR4, FLT3, HIF1A, KDR, MAPK1, MAPT, MMP2, MMP9, NOX4, RORC, THPO |
BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 3.379E-05 | 3.935E-03 | ALOX15, AXL, FABP4, FLT3, HIF1A, MAPK1, NFKB1 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.671E-05 | 4.101E-03 | CA12, CA4, CA7, ESR2, MMP1, MMP12, MMP2, MMP9, NR1H4, RORC |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.927E-05 | 4.276E-03 | CYP1A1, CYP1A2 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 4.442E-05 | 4.719E-03 | AXL, CDK1, CSNK2A1, FLT3 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 4.569E-05 | 4.806E-03 | FABP3, FABP4, FFAR4 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 5.173E-05 | 5.313E-03 | MMP1, MMP12, MMP2, MMP9 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 5.316E-05 | 5.434E-03 | ADORA1, CYP1A1, HIF1A, LMNA, MMP2, NOX4 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 5.744E-05 | 5.711E-03 | CDK1, CDK8, ESR2, NR1H4, RORC |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 6.534E-05 | 6.213E-03 | ALOX12, ALOX15 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 6.638E-05 | 6.284E-03 | IGF1R, MAPK1, MMP2, NFKB1, NOX4, NR1H4, TSHR |
BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 6.693E-05 | 6.309E-03 | ADORA1, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 6.970E-05 | 6.486E-03 | CYP1A2, MAPK1, MMP9 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 7.060E-05 | 6.486E-03 | ADK, AURKB, AXL, CDK1, CDK8, CSNK2A1, FLT3, IGF1R, KDR, MAPK1, MET, PIM1, RECQL |
MF | GO:0005488; binding | GO:0005496; steroid binding | 7.215E-05 | 6.573E-03 | ESR2, HSD17B1, NR1H4, RORC |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 7.984E-05 | 7.184E-03 | ACHE, ALOX12, ALOX15, CSNK2A1, CYP19A1, CYP1A1, HSD11B1, HSD17B1 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 9.229E-05 | 8.136E-03 | CYP19A1, CYP1A1, CYP2C19 |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 9.768E-05 | 8.489E-03 | ACHE, ADORA3, ALOX15, CDK1, CYP1A1 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.785E-05 | 8.489E-03 | CYP1A2, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.097E-04 | 9.224E-03 | CA12, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.170E-04 | 9.797E-03 | AXL, FLT3, IGF1R, KDR, MET |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.564E-09 | 9.977E-07 | HSD11B1, HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.548E-07 | 1.176E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.333E-07 | 2.624E-05 | FLT3, MMP1, MMP2, MAPK1, HIF1A, MET, MMP9, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.906E-07 | 2.624E-05 | MMP2, KDR, MAPK1, HIF1A, MMP9, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 3.269E-06 | 8.281E-05 | MMP1, MMP2, MAPK1, MMP9 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.877E-06 | 5.707E-05 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.238E-05 | 2.352E-04 | FLT3, PIM1, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.359E-05 | 3.984E-04 | FLT3, MAPK1, MET, HIF1A |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.313E-05 | 4.830E-04 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.496E-05 | 4.830E-04 | CSNK2A1, MAPK1, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 9.355E-05 | 1.016E-03 | PIM1, CYP1B1, MAPK1, MMP9, MET, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.180E-04 | 1.093E-03 | MMP2, PIM1, MAPK1, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.092E-04 | 1.093E-03 | MMP2, MAPK1, MMP9, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 8.524E-05 | 9.967E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.366E-04 | 1.093E-03 | ADORA2A, ADORA1, MAPK1, NFKB1, TSHR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.274E-04 | 1.093E-03 | MAPK1, HIF1A, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.795E-04 | 1.299E-03 | ADORA2A, KDR, MAPK1, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.519E-04 | 1.665E-03 | KDR, MAPK1, MET, NFKB1, IGF1R |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.760E-04 | 1.299E-03 | ALOX15, MAPK1, ALOX12, CYP2C19 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.293E-04 | 1.585E-03 | ADORA3, ADORA1, MAPK1, NFKB1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.754E-06 | 2.118E-04 | CA12, CA4, CA7 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.132E-05 | 6.500E-04 | CYP1A2, ALOX15, CYP2C19 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.361E-04 | 1.093E-03 | CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 8.477E-04 | 4.295E-03 | HSD11B1, HSD17B1, CYP1A2, ALOX15, CYP1A1, ADK, ALOX12, CYP2C19, CYP19A1, HSD17B10 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 3.712E-04 | 2.351E-03 | FABP4, ADORA1, TSHR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.581E-03 | 7.452E-03 | KDR, MAPK1, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 6.022E-04 | 3.520E-03 | MAPK1, MET, HIF1A |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.012E-04 | 3.047E-03 | ALOX15, ALOX12, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 7.455E-04 | 4.047E-03 | MAPK1, MET, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 7.766E-04 | 4.070E-03 | MAPK1, NFKB1, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.707E-03 | 7.633E-03 | POLB, CDK1, MAPK1, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.618E-03 | 7.452E-03 | KDR, MAPK1, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.435E-03 | 7.038E-03 | MAPK1, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.892E-03 | 8.218E-03 | CDK1, MAPK1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 6.858E-04 | 3.861E-03 | FABP3, FABP4, MMP1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MMP9; MAPK1; MMP2; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; ADORA1; FFAR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; FFAR1; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; MAPT; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; MAPT; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; ADORA2A; ADK; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NFKB1; FFAR1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; HSD11B1; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; ADORA3; MMP9; MAPK1; MMP2; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
NA: NA | GIST | NA | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |